Phase 1 Diffuse Large B Cell Lymphoma Refractory Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Follicular Lymphoma ( FL)Diffuse Large B Cell Lymphoma RefractoryPrimary Mediastinal Large B-Cell Lymphoma Refractory+3 more
GenomeFrontier Therapeutics TW Co., Ltd.18 enrolled1 locationNCT06703892
Recruiting
Phase 1
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma RefractoryTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma+8 more
Nathan Denlinger18 enrolled1 locationNCT06209619
Recruiting
Phase 1
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedEpstein-Barr Virus (EBV) Infection
Thomas Jefferson University30 enrolled1 locationNCT06789159